

Trouble viewing this email message? [Read it online.](#)



July 2025

This month's reminders

We regularly review and adjust our clinical, payment and coding policies. Review our policies and claim edits on our provider portal on Availity®.* Just go to **Payer Space > Resources > Expanded Claim Edits.**



Changes to our National Precertification List (NPL)

These changes apply to our commercial and Medicare members.

As of June 18, 2025, we require precertification for the following:

- denosumab-dssb (J3490, J3590, C9399)
- Osenvelt® (denosumab-bmwo, J3490, J3590, C9399)
- Stoboclo® (denosumab-bmwo, J3490, J3590, C9399)
- Ospomyv™ (denosumab-dssb, J3490, J3590, C9399)
- Xbryk™ (denosumab-dssb, J3490, J3590, C9399)

As of June 23, 2025, we require precertification for the following:

- Selarsdi™ (ustekinumab-aekn, J3490, J3590, C9399)
- ustekinumab-aekn (J3490, J3590, C9399)
- ustekinumab-ttwe (J3490, J3590, C9399)
- Pyzchiva® (ustekinumab-ttwe, J3490, J3590, C9399)
- Avtozma® (tocilizumab-anoh, J3490, J3590, C9399) (precertification includes the site of care (SOC))
- Steqeyma® (ustekinumab-stba, J3490, J3590, C9399)
- Yesintek™ (ustekinumab-kfce, J3490, J3590, C9399)
- Imuldosa® (ustekinumab-srlf, J3490, J3590, C9399)

Effective July 1, 2025, we'll no longer require precertification for the following:

- Electric scooters (E1230)
- Orthognathic surgery (D7296, D7940, D7941, D7943, D7944, D7945, D7946, D7947, D7948, D7949, D7950, D7955, D7995, D7996)
- Surgical management of Temporomandibular Joint (TMJ) (D7830, D7871)

For Medicare plans only, we'll no longer require precertification for the following:

- Hyperbaric oxygen therapy (HBOT) (99183, G0277)

Effective July 15, 2025, we'll require precertification for the following:

- Encelto™ (revakinagene taroretcel-lwey, J3490, J3590, C9399)

Submitting precertification requests

Submit precertification requests at least two weeks in advance and include the actual date of service in the request. To save time, request precertification online through [our provider portal on Availity](#).* Doing so is fast, secure and simple.

You can also use your practice's Electronic Medical Record (EMR) system if it's set up for electronic precertification requests. Use our "Search by CPT® code" function on our Precertification Lists page to find out if the code requires [precertification](#).**

If you need precertification for a specialty drug for a commercial or Medicare member, submit your request through Novologix®, also available on Availity.

*Availity® is available only to providers in the U.S. and its territories.

**CPT® is a registered trademark of the American Medical Association. 2024 All rights reserved.

Note to Maine and Vermont providers: For commercial plans, your effective date for routine changes described in this article will be the statutory date of January 1, April 1, July 1 or October 1, whichever date follows the effective date(s) referred to in this article. Changes required by state or federal law, or pursuant to revisions of Current Procedural Terminology (CPT®) codes published by the American Medical Association, may be effective outside the statutory dates outlined above.



Site-of-care prior authorization timeline changes for certain oncology drugs begin on October 1

On October 1, 2025, we're updating our initial prior authorization approval timeline for certain oncology medications administered in an outpatient hospital site. These changes will affect only those patients who are new to therapy after October 1. Certain oncology drugs will have an initial approval of 90 days when a place of service is outpatient hospital.

Affected drugs

The affected oncology drugs are the following Immune Checkpoint Inhibitors:

- Bavencio
- Imfinzi
- Jemperli
- Keytruda
- Libtayo
- Loqtorzi
- Opdivo
- Opdivo Qvantig
- Opdualag
- Tecentriq
- Tecentriq Hybreza
- Tevimbra
- Unloxcyt
- Yervoy
- Zynyz

Note that this change will affect only new approvals, not existing ones.

More information

You can access the Site of Care for Specialty Drug Administration policy and the medications to which this policy applies on our [Drug infusion/injection site of care policy page](#).



You can always find this information on our provider portal on Availity.*

You can also use our Code Edit Lookup tools on Availity®. Just go to **Payer Space > Applications > Code Edit Lookup Tools**. Keep your Aetna™ provider ID number handy to access them.

[Availity portal](#)

*Availity® is available only to providers in the U.S. and its territories.

**CPT® is a registered trademark of the American Medical Association. 2024 All rights reserved.

Aetna® is the brand name used for products and services provided by one or more of the Aetna group of companies, including Aetna Life Insurance Company and its affiliates (Aetna).

All registered company names, products and services are the property of their respective owners.

Help/contact us: If you have any questions, please [contact us](#).

Want to stop receiving email messages like these? [Unsubscribe](#) at any time.

We are located at 151 Farmington Avenue, Hartford, CT 06156.

[Privacy Statement](#) | [Terms of Use](#) | [Privacy Information](#)

©2025 Aetna Inc.
5384116-01-01

Name: July 2025 OLU provider newsletter

Subject: Aetna monthly OfficeLink Updates, July 2025 -- policy changes and updates

Preheader: Learn about important policy updates, material changes and amendments

Trouble viewing this email message? [Read it online.](#)



July 2025

This month's reminders

We regularly review and adjust our clinical, payment and coding policies. Review our policies and claim edits on our provider portal on Availity®.* Just go to **Payer Space > Resources > Expanded Claim Edits.**



Changes to our National Precertification List (NPL)

These changes apply to our commercial and Medicare members.

As of June 18, 2025, we require precertification for the following:

- denosumab-dssb (J3490, J3590, C9399)

- Osenvelt® (denosumab-bmwo, J3490, J3590, C9399)

- Stoboclo® (denosumab-bmwo, J3490, J3590, C9399)

- Ospomyv™ (denosumab-dssb, J3490, J3590, C9399)

- Xbryk™ (denosumab-dssb, J3490, J3590, C9399)

As of June 23, 2025, we require precertification for the following:

- Selarsdi™ (ustekinumab-aekn, J3490, J3590, C9399)

- ustekinumab-aekn (J3490, J3590, C9399)

- ustekinumab-ttwe (J3490, J3590, C9399)

- Pyzchiva® (ustekinumab-ttwe, J3490, J3590, C9399)

- Avtozma® (tocilizumab-anoh, J3490, J3590, C9399)

(precertification includes the site of care (SOC))

- Steqeyma® (ustekinumab-stba, J3490, J3590, C9399)

- Yesintek™ (ustekinumab-kfce, J3490, J3590, C9399)

- Imuldosa® (ustekinumab-srlf, J3490, J3590, C9399)

Effective July 1, 2025, we'll no longer require precertification for the following:

- Electric scooters (E1230)

- Orthognathic surgery (D7296, D7940, D7941, D7943, D7944, D7945, D7946, D7947, D7948, D7949, D7950, D7955, D7995, D7996)

- Surgical management of Temporomandibular Joint (TMJ) (D7830, D7871)

For Medicare plans only, we'll no longer require precertification for the following:

- Hyperbaric oxygen therapy (HBOT) (99183, G0277)

Effective July 15, 2025, we'll require precertification for the following:

- Encelto™ (revakinagene taroretcel-lwey, J3490, J3590, C9399)

Submitting precertification requests

Submit precertification requests at least two weeks in advance and include the actual date of service in the request. To save time, request precertification online through [our provider portal on Availity](#).* Doing so is fast, secure and simple.


You can also use your practice's Electronic Medical Record (EMR) system if it's set up for electronic precertification requests. Use our "Search by CPT® code" function on our Precertification Lists page to find out if the code requires [precertification](#).**

If you need precertification for a specialty drug for a commercial or Medicare member, submit your request through Novologix®, also available on Availity.

*Availity® is available only to providers in the U.S. and its territories.

**CPT® is a registered trademark of the American Medical Association. 2024 All rights reserved.

Note to Maine and Vermont providers: For commercial plans, your effective date for routine changes described in this article will be the statutory date of January 1, April 1, July 1 or October 1, whichever date follows the effective date(s) referred to in this article. Changes required by state or federal law, or pursuant to revisions of Current Procedural Terminology (CPT®) codes published by the American Medical Association, may be effective outside the statutory dates outlined above.



Site-of-care prior authorization timeline changes for certain oncology drugs begin on October 1

On October 1, 2025, we're updating our initial prior authorization approval timeline for certain oncology medications administered in an outpatient hospital site. These changes will affect only those patients who are new to therapy after October 1. Certain oncology drugs will have an initial approval of 90 days when a place of service is outpatient hospital.

Affected drugs

The affected oncology drugs are the following Immune Checkpoint Inhibitors:

- Bavencio

- Imfinzi

- Jemperli

- Keytruda

- Libtayo

- Loqtorzi

- Opdivo

- Opdivo Qvantig

- Opdualag

- Tecentriq

- Tecentriq Hybreza

- Tevimbra

- Unloxcyt

- Yervoy

- Zynyz

Note that this change will affect only new approvals, not existing ones.

More information

You can access the Site of Care for Specialty Drug Administration policy and the medications to which this policy applies on our [Drug infusion/injection site of care policy page](#).

You can always find this information on our provider portal on Availity.*

You can also use our Code Edit Lookup tools on Availity®. Just go to **Payer Space > Applications > Code Edit Lookup Tools**. Keep your Aetna provider ID number handy to access them.

[Availity portal](#)

*Availity® is available only to providers in the U.S. and its territories.

**CPT® is a registered trademark of the American Medical Association. 2024 All rights reserved.

Aetna® is the brand name used for products and services provided by one or more of the Aetna group of companies, including Aetna Life Insurance Company and its affiliates (Aetna).

All registered company names, products and services are the property of their respective owners.

Help/contact us: If you have any questions, please [contact us](#).

Want to stop receiving email messages like these? [Unsubscribe](#) at any time.

We are located at 151 Farmington Avenue, Hartford, CT 06156.

[Privacy Statement](#) | [Terms of Use](#) | [Privacy Information](#)

©2025 Aetna Inc.
5384116-01-01